POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed

Imfinzi and tremelimumab plus chemotherapy improved PFS in first-line NSCLC, but overall survival is continuing to be assessed, and AstraZeneca did not clarify how the triple combination compared to Imfinzi alone with chemotherapy.

SC1910_Cyclists_170970920_1200.jpg
AstraZeneca hopes to catch up to the leaders in metastatic NSCLC • Source: Shutterstock

AstraZeneca PLC’s Imfinzi (durvalumab) could be poised for expanded use in the big first-line metastatic non-small cell lung cancer market now that, at long last, a trial testing the PD-L1 inhibitor with AstraZeneca’s CTLA-4 antibody tremelimumab in first-line NSCLC met the primary endpoint of improvement in progression-free survival.

The company released the top-line results of the Phase III POSEIDON trial on 28 October, but the trial is continuing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category